Meeting of the Advisory Committee on Immunization Practices, 2002-2003 [2025-00349]
Download as PDF
khammond on DSK9W7S144PROD with NOTICES
2002
Federal Register / Vol. 90, No. 6 / Friday, January 10, 2025 / Notices
The National Marine Fisheries Service
(NMFS) has adopted the Bureau of
Ocean Energy Management’s Final EIS
No. 20240137 filed 07/26/2024 with the
Environmental Protection Agency. The
NMFS was a cooperating agency on this
project. Therefore, republication of the
document is not necessary under
Section 1506.3(b)(2) of the CEQ
regulations.
EIS No. 20250002, Draft, FHWA, HI,
Honoapi’ilani Highway Improvements
Project, Comment Period Ends: 02/24/
2025, Contact: Paul La Farga 808–
541–2704.
EIS No. 20250003, Final, DHS, IBWC,
GSA, TX, Proposed Modernization of
the Bridge of the Americas Land Port
of Entry in El Paso Texas, Review
Period Ends: 02/10/2025, Contact:
Karla R. Carmichael 817–996–9475.
EIS No. 20250004, Draft, USACE, MD,
Sparrows Point Container Terminal,
Comment Period Ends: 03/21/2025,
Contact: Maria N. Teresi 410–962–
4252.
EIS No. 20250005, Draft, BLM, OR,
Bridge Creek Area Allotment
Management Plans, Comment Period
Ends: 02/24/2025, Contact: Don Rotell
541–573–4400.
EIS No. 20250006, Final, USFWS, OR,
Elliott State Research Forest Habitat
Conservation Plan, Review Period
Ends: 02/10/2025, Contact: Shauna
Everett 503–231–6949.
EIS No. 20250007, Final, USFS, ID,
Land Management Plan for the Nez
Perce-Clearwater National Forests,
Review Period Ends: 02/10/2025,
Contact: Sara Daugherty 208–963–
4206.
EIS No. 20250008, Draft, BLM, AZ,
Ranegras Plains Energy Center Project,
Comment Period Ends: 02/24/2025,
Contact: Derek Eysenbach 602–417–
9505.
EIS No. 20250009, Draft, NNSA, NM,
Draft Site-Wide Environmental Impact
Statement for Continued Operation of
Los Alamos National Laboratory,
Comment Period Ends: 03/11/2025,
Contact: Stephen Hoffman 505–665–
8980.
EIS No. 20250010, Draft, FTA, TX,
Austin Light Rail Phase 1 Project,
Comment Period Ends: 03/11/2025,
Contact: Terence Plaskon 817–978–
0573.
EIS No. 20250011, Final, TVA, MS, New
Caledonia Gas Plant Project, Review
Period Ends: 02/10/2025, Contact:
Erica McLamb 423–751–8022.
EIS No. 20250012, Final, OSM, MT,
Spring Creek Mine, Review Period
Ends: 02/10/2025, Contact: Marcelo
Calle 303–236–2929.
Amended Notice:
VerDate Sep<11>2014
17:28 Jan 08, 2025
Jkt 265001
EIS No. 20240148, Draft, APHIS, PRO,
Outbreak Response Activities for
Highly Pathogenic Avian Influenza
Outbreaks in Poultry in the United
States and U.S. Territories, Comment
Period Ends: 01/17/2025, Contact:
Chelsea Bare 515–337–6128.
Revision to FR Notice published 08/
16/2024; APHIS has reopened the
comment period to end on 01/17/2025.
Dated: January 6, 2025.
Mark Austin,
Acting Director, NEPA Compliance Division,
Office of Federal Activities.
[FR Doc. 2025–00363 Filed 1–8–25; 8:45 am]
BILLING CODE 6560–50–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2025–0003]
Meeting of the Advisory Committee on
Immunization Practices
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. Time will be available for public
comment.
DATES: The meeting will be held on
February 26, 2025, from 8 a.m. to 5:10
p.m., EST, February 27, 2025, from 8
a.m. to 5 p.m., EST, and February 28,
2025, from 8 a.m. to 11:25 a.m., EST
(times subject to change; see the ACIP
website for updates: https://
www.cdc.gov/acip).
Written comments must be received
between February 3–17, 2025.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2025–
0003, by either of the methods listed
below. CDC does not accept comments
by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Ms. Stephanie Thomas, ACIP
Meeting, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop H24–8, Atlanta, Georgia
30329–4027. Attn: Docket No. CDC–
2025–0003.
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Instructions: All submissions received
must include the Agency name and
docket number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
The meeting will be webcast live via
the World Wide Web. The webcast link
can be found on the ACIP website at
https://www.cdc.gov/acip.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, Committee
Management Specialist, Advisory
Committee on Immunization Practices,
National Center for Immunization and
Respiratory Diseases, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H24–8,
Atlanta, Georgia 30329–4027.
Telephone: (404) 639–8836; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee on
Immunization Practices (ACIP) is
charged with advising the Director,
Centers for Disease Control and
Prevention (CDC), on the use of
immunizing agents. In addition, under
42 U.S.C. 1396s, the Committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children program, along
with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under applicable provisions of the
Affordable Care Act and section 2713 of
the Public Health Service Act,
immunization recommendations of
ACIP that have been approved by the
Director, CDC, and appear on CDC
immunization schedules generally must
be covered by applicable health plans.
Matters to be Considered: The agenda
will include discussions on
chikungunya vaccines, COVID–19
vaccines, cytomegalovirus (CMV)
vaccine, Human papillomavirus (HPV)
vaccines, influenza vaccines,
meningococcal vaccines, mpox
vaccines, pneumococcal vaccines,
Respiratory Syncytial Virus (RSV)
vaccines for adults, RSV vaccines for
maternal and pediatric populations, and
Lyme disease. Recommendation votes
are scheduled for meningococcal
vaccines, chikungunya vaccines,
influenza vaccines, and RSV vaccines
for adults. Vaccines for Children (VFC)
votes are scheduled for influenza and
meningococcal vaccines. Agenda items
E:\FR\FM\10JAN1.SGM
10JAN1
Federal Register / Vol. 90, No. 6 / Friday, January 10, 2025 / Notices
khammond on DSK9W7S144PROD with NOTICES
are subject to change as priorities
dictate. For more information on the
meeting agenda, visit https://
www.cdc.gov/acip/meetings/.
Meeting Information: The meeting
will be webcast live via the World Wide
Web. For more information on ACIP,
please visit the ACIP website: https://
www.cdc.gov/acip.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near-duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments February 3–17, 2025. Written
comments must be received by February
17, 2025.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes, including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the February 26–28,
2025, ACIP meeting must submit a
request at https://www.cdc.gov/acip/
meetings/ between February
3–17, 2025, and no later than 11:59
p.m., EST, February 17, 2025 according
to the instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a random draw
to determine the speakers for the
VerDate Sep<11>2014
17:28 Jan 08, 2025
Jkt 265001
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by February 19, 2025. To accommodate
the significant interest in participation
in the oral public comment session of
ACIP meetings, each speaker will be
limited to three minutes, and each
speaker may speak only once per
meeting.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2025–00349 Filed 1–8–25; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–7077–N]
Announcement of the Advisory Panel
on Outreach and Education (APOE)
Virtual Meeting
Centers for Medicare &
Medicaid Services (CMS), Health and
Human Services (HHS).
ACTION: Notice.
AGENCY:
This notice announces the
next meeting of the Advisory Panel on
Outreach and Education (APOE) (the
Panel) in accordance with the Federal
Advisory Committee Act. The Panel
advises and makes recommendations to
the Secretary of the U.S. Department of
Health and Human Services (HHS) (the
Secretary) and the Administrator of the
Centers for Medicare & Medicaid
Services (CMS) on opportunities to
enhance the effectiveness of consumer
education strategies concerning the
Health Insurance Marketplace®,1
Medicare, Medicaid, and the Children’s
Health Insurance Program (CHIP). This
meeting is open to the public.
DATES:
SUMMARY:
1 The Health Insurance Marketplace® is a
registered service mark of the U.S. Department of
Health and Human Services.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
2003
Meeting Date: Thursday, February 6,
2025 from 12:30 p.m. to 5 p.m. eastern
standard time (e.s.t).
Deadline for Meeting Registration,
Presentations, Special
Accommodations, and Comments:
Thursday, January 23, 2025 by 5 p.m.
e.s.t.
ADDRESSES:
Meeting Location: Virtual. All those
who RSVP will receive the link to
attend.
Presentations and Written Comments:
Presentations and written comments
should be submitted to: Hailey Gutzmer,
Acting Designated Federal Official
(DFO), Office of Communications,
Centers for Medicare & Medicaid
Services, 200 Independence Avenue
SW, Mailstop 315D.02, Washington, DC
20201, 410–786–1307, or via email at
APOE@cms.hhs.gov.
Registration: Persons wishing to
attend this meeting must register at the
website https://CMS-APOEFebruary2025.rsvpify.com or by
contacting the DFO listed in the FOR
FURTHER INFORMATION CONTACT section of
this notice, by the date listed in the
DATES section of this notice. Individuals
requiring sign language interpretation or
other special accommodations should
contact the DFO at the address listed in
the ADDRESSES section of this notice by
the date listed in the DATES section of
this notice.
FOR FURTHER INFORMATION CONTACT:
Hailey Gutzmer, Acting Designated
Federal Official, Office of
Communications, Centers for Medicare
& Medicaid Services, 200 Independence
Avenue SW, Mailstop 315D.02,
Washington, DC 20201, 410–786–1307,
or via email at APOE@cms.hhs.gov.
Additional information about the
APOE is available at: https://
www.cms.gov/Regulations-andGuidance/Guidance/FACA/APOE. Press
inquiries are handled through the CMS
Press Office at (202) 690–6145.
SUPPLEMENTARY INFORMATION:
I. Background and Charter Renewal
Information
A. Background
The Advisory Panel on Outreach and
Education (APOE) (the Panel) is
governed by the provisions of the
Federal Advisory Committee Act
(FACA) (Pub. L. 92–463), as amended (5
U.S.C. Appendix 2), which sets forth
standards for the formation and use of
federal advisory committees. The Panel
is authorized by section 1114(f) of the
Social Security Act (the Act) (42 U.S.C.
1314(f)) and section 222 of the Public
Health Service Act (42 U.S.C. 217a).
E:\FR\FM\10JAN1.SGM
10JAN1
Agencies
[Federal Register Volume 90, Number 6 (Friday, January 10, 2025)]
[Notices]
[Pages 2002-2003]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00349]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2025-0003]
Meeting of the Advisory Committee on Immunization Practices
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. Time will be available for
public comment.
DATES: The meeting will be held on February 26, 2025, from 8 a.m. to
5:10 p.m., EST, February 27, 2025, from 8 a.m. to 5 p.m., EST, and
February 28, 2025, from 8 a.m. to 11:25 a.m., EST (times subject to
change; see the ACIP website for updates: https://www.cdc.gov/acip).
Written comments must be received between February 3-17, 2025.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2025-
0003, by either of the methods listed below. CDC does not accept
comments by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8,
Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2025-0003.
Instructions: All submissions received must include the Agency name
and docket number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
The meeting will be webcast live via the World Wide Web. The
webcast link can be found on the ACIP website at https://www.cdc.gov/acip.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management
Specialist, Advisory Committee on Immunization Practices, National
Center for Immunization and Respiratory Diseases, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta,
Georgia 30329-4027. Telephone: (404) 639-8836; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee on Immunization Practices (ACIP) is
charged with advising the Director, Centers for Disease Control and
Prevention (CDC), on the use of immunizing agents. In addition, under
42 U.S.C. 1396s, the Committee is mandated to establish and
periodically review and, as appropriate, revise the list of vaccines
for administration to vaccine-eligible children through the Vaccines
for Children program, along with schedules regarding dosing interval,
dosage, and contraindications to administration of vaccines. Further,
under applicable provisions of the Affordable Care Act and section 2713
of the Public Health Service Act, immunization recommendations of ACIP
that have been approved by the Director, CDC, and appear on CDC
immunization schedules generally must be covered by applicable health
plans.
Matters to be Considered: The agenda will include discussions on
chikungunya vaccines, COVID-19 vaccines, cytomegalovirus (CMV) vaccine,
Human papillomavirus (HPV) vaccines, influenza vaccines, meningococcal
vaccines, mpox vaccines, pneumococcal vaccines, Respiratory Syncytial
Virus (RSV) vaccines for adults, RSV vaccines for maternal and
pediatric populations, and Lyme disease. Recommendation votes are
scheduled for meningococcal vaccines, chikungunya vaccines, influenza
vaccines, and RSV vaccines for adults. Vaccines for Children (VFC)
votes are scheduled for influenza and meningococcal vaccines. Agenda
items
[[Page 2003]]
are subject to change as priorities dictate. For more information on
the meeting agenda, visit https://www.cdc.gov/acip/meetings/.
Meeting Information: The meeting will be webcast live via the World
Wide Web. For more information on ACIP, please visit the ACIP website:
https://www.cdc.gov/acip.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near-duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments February 3-17, 2025. Written comments must be received
by February 17, 2025.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes, including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the February 26-28, 2025, ACIP meeting must
submit a request at https://www.cdc.gov/acip/meetings/
between February 3-17, 2025, and no later than 11:59 p.m., EST,
February 17, 2025 according to the instructions provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
random draw to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by February 19, 2025. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to three minutes, and each
speaker may speak only once per meeting.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2025-00349 Filed 1-8-25; 8:45 am]
BILLING CODE 4163-18-P